- AGC Biologics and Repair Biotechnologies have entered a partnership to develop and manufacture a novel mRNA therapy targeting atherosclerotic plaque.
- The collaboration will use AGC Biologics’ mRNA capabilities, from plasmid DNA to lipid nanoparticle drug product.
AGC Biologics has entered a partnership with Repair Biotechnologies to develop and manufacture a novel mRNA therapy designed to stabilise and reduce atherosclerotic plaque. According to the press release, rupture of unstable plaque leading to heart attack or stroke accounts for 27% of all human mortality.
The collaboration focuses on advancing an mRNA therapeutic aimed at addressing atherosclerotic cardiovascular disease. Repair Biotechnologies said manufacturing is a critical component of this development effort. “Developing a novel mRNA therapeutic as a part of the vital goal of curing atherosclerotic cardiovascular disease is a complex task, and robust manufacturing is critical to our progress,” said Reason, CEO and co-founder of Repair Biotechnologies.
AGC Biologics stated that its approach consolidates the full production process to provide a streamlined path from development to the clinic. The partnership will utilise the company’s mRNA manufacturing platform, which manages the process from plasmid DNA through to lipid nanoparticle-encapsulated drug product.
“For clients like Repair Biotechnologies, we can be the most cost-effective, reliable, cGMP provider that can take life-saving mRNA treatments through the journey from preclinical to commercial stages.”
Alberto Santagostino, CEO of AGC Biologics
The AGC Biologics Heidelberg site will support production using single-use equipment under GMP standards aligned with the European Medicines Agency and U.S. Food and Drug Administration guidelines.
